Literature DB >> 26476350

Rap1 GTPase Inhibits Tumor Necrosis Factor-α-Induced Choroidal Endothelial Migration via NADPH Oxidase- and NF-κB-Dependent Activation of Rac1.

Haibo Wang1, Lori Fotheringham1, Erika S Wittchen2, M Elizabeth Hartnett3.   

Abstract

Macrophage-derived tumor necrosis factor (TNF)-α has been found in choroidal neovascularization (CNV) surgically removed from patients with age-related macular degeneration. However, the role of TNF-α in CNV development remains unclear. In a murine laser-induced CNV model, compared with un-lasered controls, TNF-α mRNA was increased in retinal pigment epithelial and choroidal tissue, and TNF-α colocalized with lectin-stained migrating choroidal endothelial cells (CECs). Inhibition of TNF-α with a neutralizing antibody reduced CNV volume and reactive oxygen species (ROS) level around CNV. In CECs, pretreatment with the antioxidant apocynin or knockdown of p22phox, a subunit of NADPH oxidase, inhibited TNF-α-induced ROS generation. Apocynin reduced TNF-α-induced NF-κB and Rac1 activation, and inhibited TNF-α-induced CEC migration. TNF-α-induced Rac1 activation and CEC migration were inhibited by NF-κB inhibitor Bay11-7082. Overexpression of Rap1a prevented TNF-α-induced ROS generation and reduced NF-κB and Rac1 activation. Activation of Rap1 by 8-(4-chlorophenylthio)adenosine-2'-O-Me-cAMP prevented TNF-α-induced CEC migration and reduced laser-induced CNV volume, ROS generation, and activation of NF-κB and Rac1. These findings provide evidence that active Rap1a inhibits TNF-α-induced CEC migration by inhibiting NADPH oxidase-dependent NF-κB and Rac1 activation and suggests that Rap1a de-escalates CNV development by interfering with ROS-dependent signaling in several steps of the pathogenic process.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26476350      PMCID: PMC4729241          DOI: 10.1016/j.ajpath.2015.08.017

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  The role of vascular endothelial growth factor-induced activation of NADPH oxidase in choroidal endothelial cells and choroidal neovascularization.

Authors:  Elizabeth Monaghan-Benson; John Hartmann; Aleksandr E Vendrov; Steve Budd; Grace Byfield; Augustus Parker; Faisal Ahmad; Wei Huang; Marschall Runge; Keith Burridge; Nageswara Madamanchi; M Elizabeth Hartnett
Journal:  Am J Pathol       Date:  2010-08-27       Impact factor: 4.307

2.  Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105.

Authors:  Peter Lichtlen; Tim T Lam; T Michael Nork; Tim Streit; David M Urech
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-14       Impact factor: 4.799

3.  Regression of neovascular age-related macular degeneration following infliximab therapy.

Authors:  Nikos N Markomichelakis; Panagiotis G Theodossiadis; Petros P Sfikakis
Journal:  Am J Ophthalmol       Date:  2005-03       Impact factor: 5.258

4.  Upregulation of CCR3 by age-related stresses promotes choroidal endothelial cell migration via VEGF-dependent and -independent signaling.

Authors:  Haibo Wang; Erika S Wittchen; Yanchao Jiang; Balamurali Ambati; Hans E Grossniklaus; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-21       Impact factor: 4.799

5.  Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity.

Authors:  Frank Weinberg; Robert Hamanaka; William W Wheaton; Samuel Weinberg; Joy Joseph; Marcos Lopez; Balaraman Kalyanaraman; Gökhan M Mutlu; G R Scott Budinger; Navdeep S Chandel
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

6.  Mitochondrial ROS govern the LPS-induced pro-inflammatory response in microglia cells by regulating MAPK and NF-κB pathways.

Authors:  Junghyung Park; Ju-Sik Min; Bokyung Kim; Un-Bin Chae; Jong Won Yun; Myung-Sook Choi; Il-Keun Kong; Kyu-Tae Chang; Dong-Seok Lee
Journal:  Neurosci Lett       Date:  2014-10-22       Impact factor: 3.046

Review 7.  RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis.

Authors:  Hemant K Bid; Ryan D Roberts; Parmeet K Manchanda; Peter J Houghton
Journal:  Mol Cancer Ther       Date:  2013-09-26       Impact factor: 6.261

8.  Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors.

Authors:  Gena Damento; Shaheen C Kavoussi; Miguel A Materin; Diva R Salomão; Polly A Quiram; Saranya Balasubramaniam; Soranya Balasubramaniam; Jose S Pulido
Journal:  Mayo Clin Proc       Date:  2014-11-03       Impact factor: 7.616

9.  Suppression of TNF-alpha-induced apoptosis by NF-kappaB.

Authors:  D J Van Antwerp; S J Martin; T Kafri; D R Green; I M Verma
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

10.  Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration.

Authors:  Panagiotis G Theodossiadis; Vasilios S Liarakos; Petros P Sfikakis; Ioannis A Vergados; George P Theodossiadis
Journal:  Am J Ophthalmol       Date:  2009-02-10       Impact factor: 5.258

View more
  23 in total

1.  The trafficking protein JFC1 regulates Rac1-GTP localization at the uropod controlling neutrophil chemotaxis and in vivo migration.

Authors:  Mahalakshmi Ramadass; Jennifer L Johnson; Alex Marki; Jinzhong Zhang; Dennis Wolf; William B Kiosses; Kersi Pestonjamasp; Klaus Ley; Sergio D Catz
Journal:  J Leukoc Biol       Date:  2019-02-12       Impact factor: 4.962

2.  Histopathological and ophthalmoscopic evaluation of apocynin on experimental proliferative vitreoretinopathy in rabbit eyes.

Authors:  Murat Atabey Ozer; Nihat Polat; Serkan Ozen; Tevfik Ogurel; Hakan Parlakpinar; Nigar Vardi
Journal:  Int Ophthalmol       Date:  2016-08-05       Impact factor: 2.031

Review 3.  Rap1 in endothelial biology.

Authors:  Magdalena Chrzanowska-Wodnicka
Journal:  Curr Opin Hematol       Date:  2017-05       Impact factor: 3.284

4.  Evaluation of active Rac1 levels in cancer cells: A case of misleading conclusions from immunofluorescence analysis.

Authors:  Martin J Baker; Mariana Cooke; Gabriel Kreider-Letterman; Rafael Garcia-Mata; Paul A Janmey; Marcelo G Kazanietz
Journal:  J Biol Chem       Date:  2020-08-14       Impact factor: 5.157

5.  Effect of integrin α5β1 inhibition on SDF-l/CXCR4-mediated choroidal neovascularization.

Authors:  Yang Lyu; Wen-Qin Xu; Li-Juan Sun; Xiao-Yan Pan; Jian Zhang; Yu-Sheng Wang
Journal:  Int J Ophthalmol       Date:  2018-05-18       Impact factor: 1.779

6.  IQGAP1 causes choroidal neovascularization by sustaining VEGFR2-mediated Rac1 activation.

Authors:  Haibo Wang; Aniket Ramshekar; Eric Kunz; David B Sacks; M Elizabeth Hartnett
Journal:  Angiogenesis       Date:  2020-08-11       Impact factor: 9.596

7.  7-ketocholesterol induces endothelial-mesenchymal transition and promotes fibrosis: implications in neovascular age-related macular degeneration and treatment.

Authors:  Haibo Wang; Aniket Ramshekar; Eric Kunz; M Elizabeth Hartnett
Journal:  Angiogenesis       Date:  2021-02-28       Impact factor: 10.658

8.  Rap1a Regulates Cardiac Fibroblast Contraction of 3D Diabetic Collagen Matrices by Increased Activation of the AGE/RAGE Cascade.

Authors:  Stephanie D Burr; James A Stewart
Journal:  Cells       Date:  2021-05-22       Impact factor: 6.600

9.  Active Rap1-mediated inhibition of choroidal neovascularization requires interactions with IQGAP1 in choroidal endothelial cells.

Authors:  Aniket Ramshekar; Haibo Wang; Eric Kunz; Christian Pappas; Gregory S Hageman; Brahim Chaqour; David B Sacks; M Elizabeth Hartnett
Journal:  FASEB J       Date:  2021-07       Impact factor: 5.834

10.  MicroRNA-224 promotes the sensitivity of osteosarcoma cells to cisplatin by targeting Rac1.

Authors:  Shuo Geng; Lina Gu; Fang Ju; Hepeng Zhang; Yiwen Wang; Han Tang; ZhengGang Bi; Chenglin Yang
Journal:  J Cell Mol Med       Date:  2016-05-25       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.